SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...

Please provide your email address to receive an email when new articles are posted on . MONTREAL — Spiriva Respimat, as an add-on to inhaled corticosteroids or long-acting beta2 agonists, reduced the ...

The US Food and Drug Administration (FDA) yesterday approved an inhalation spray version of tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for maintenance treatment of chronic obstructive ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiriva Respimat contains the active ingredient tiotropium. Spiriva ...

This approval was based on efficacy and safety data from the Phase 2 and Phase 3 UniTinA-asthma clinical development program. The Food and Drug Administration (FDA) has approved Spiriva Respimat ...

RIDGEFIELD, Conn., September 16, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Spiriva Respimat for the long-term, once-daily treatment of asthma in patients aged 12 years ...

RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...

(Reuters) -Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker said on ...

DUBLIN--(BUSINESS WIRE)--The "Spiriva" report has been added to ResearchAndMarkets.com's offering. Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for ...